Effect of 2-(1-piperazinyl)-4H-pyrido[1,2-a]pyrimidin4-one (AP155) on human platelets in vitro

Biochemical Pharmacology

Volumn 53, Issue 11, 1997, Pages 1667-1672

  Leoncini, Giuliana ^a   Signorello, Maria Grazia ^a   Roma, Giorgio ^b   Di Braccio, Mario ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Antiplatelet activity; CAMP; CAMP phosphodiesterase; Mode of action; Pyridopyrimidine derivative

Indexed keywords

2 (1 PIPERAZINYL) 4H PYRIDO[1,2 A]PYRIMIDIN 4 ONE; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; AP 155; CALCIUM ION; COLLAGEN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; FIBRINOGEN; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHODIESTERASE; PYRIMIDINE DERIVATIVE; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA;

EID: 0030841710     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00019-1     Document Type: Article

References (21)

1. Roma G, Di Braccio M, Leoncini G and Aprile B, 1,2-Fused pyrimidines VI. Substituted 2-amino-4H-pyrido[1,2-a]pyrimidin-4-ones with antiplatelet activity. Il Farmaco 48: 1225-1238, 1993.
2. Di Braccio M, Roma G and Leoncini G, 1,2-Fused pyrimidines VII. 3-(Dialkylamino)-1H-pyrimido[1,2-a]quinolin-1-ones and 2-(dialkylamino)-4H-pyrimido[2,1-a]isoquinolin-4-ones as antiplatelet compounds. Eur J Med Chem 30: 27-38, 1995.
3. Leoncini G, Maresca M, Buzzi E, Piana A and Armani U, Platelets of patients affected with essential thrombocythemia are abnormal in plasma membrane and adenine nucleotide content. Eur J Hemat 44: 115-119, 1990.
4. Born GVR, Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194: 927-929, 1962.
5. Leoncini G, Maresca M, Colao C, Buzzi E, Mazzei M and Balbi A, Antiplatelet effect of 2-(diethylamino)-7-hydroxychromone. Pharmacol Res 23: 139-148, 1991.
6. ++ fluxes. J Pharmacol Exp Ther 243: 767-774, 1987.
7. Yamaguchi A, Suzuki H, Tanoue K and Yamazaki H, Simple method of aequorin loading into platelets using dimethyl sulfoxide. Thromb Res 44: 165-174, 1986.
8. Scatchard G, The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51: 543-548, 1949.
9. Benjamin CW, Lin AH, Morris J, Wishka DG and Gorman RR, 2-Aminochromones block human platelet aggregation by inhibiting cyclic AMP-dependent phosphodiesterase leading to reduced platelet phospholipase C activity. J Pharmacol Exp Ther 265: 457-462, 1993.
10. Packham MA and Mustard JF, The role of platelets in the development and complications of atherosclerosis. Semin Hematol 23: 8-26, 1986.
11. White JG, Platelets and atherosclerosis. Eur J Clin Invest 24: 25-29, 1994.
12. Siess W and Lapetina E, Functional relationship between cyclic AMP-dependent protein phosphorylation and platelet inhibition. Biochem J 270: 815-819, 1990.
13. Siess W, Molecular mechanisms of platelet activation. Physiol Rev 69: 58-178, 1989.
14. Gillespie E, Anagrelide: a potent and selective inhibitor of platelet cyclic cAMP phosphodiesterase enzyme activity. Biochem Pharmacol 37: 2866-2868, 1988.
15. Seiler S, Gillespie E, Arnold AJ, Brassard CL, Meanwell NA and Fleming JS, Imidazoquinoline derivatives: Potent inhibitors of platelet cAMP phosphodiesterase which elevate cAMP levels and activate protein kinase in platelets. Thromb Res 62: 31-42, 1991.
16. 2+ Homeostasis and intracellular pools in human platelets. In: Mechanisms of Platelet Activation and Control (Eds. Authi KS, Watson SP and Kakkar VV), pp. 83-98, Plenum Press, New York, 1993.
17. Yada Y, Nagao S, Okano Y and Nozawa Y, Inhibition by cyclic AMP of guanine nucleotide induced activation of phosphoinositide specific phospholipase C in human platelets. FEBS Lett 242: 368-372, 1989.
18. ++ release from platelets membranes. Biochem Biophys Res Commun 184: 893-899, 1992.
19. Hawiger J, Parkinson S and Timmons S, Prostacyclin inhibits mobilization of fibrinogen binding sites on human ADP and thrombin treated platelets. Nature 283: 193-197, 1980.
20. Graber SE and Hawiger J, Evidence that changes in platelet cyclic AMP levels regulate the fibrinogen receptor on human platelets. J Biol Chem 257: 14606-14609, 1982.
21. Niiya K, Hodson E, Bader R, Byers-Ward V, Koziol JA, Plow EF and Ruggeri ZM, Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation. Blood 70: 475-483, 1987.